Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Sigyn Therapy™
Drug Enhancement Technologies
Overview
ImmunePrep™
ChemoPrep™
ChemoPure™
News
Press Releases
Presentations
Resources
Media
Investors
Overview
News & Events
Company Info
Email Alerts
Financial Info
Stock Data
SEC Filings
Governance
Contact
CEO Notes
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
Email Alerts
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Stock Data
Quote
Charts
Historical Data
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Governance
Overview
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-Q
10-Q/A
3
4
4/A
424B3
8-A12G
8-K
8-K/A
CORRESP
D
D/A
DEF 14A
DEF 14C
EFFECT
NT 10-K
NT 10-Q
POS AM
PRE 14A
PRE 14C
RW
S-1
S-1/A
SC 13G
SC 13G/A
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Date
Form
Description
PDF
XBRL
Pages
11/07/22
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-4.2
EX-10.2
EX-10.4
EX-10.5
EX-10.6
EX-10.16
EX-10.17
EX-10.18
EX-10.19
EX-10.20
EX-10.21
EX-23.1
551
10/05/22
8-K
Current report filing
2
08/30/22
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-4.2
EX-10.21
EX-10.22
EX-10.23
EX-10.24
EX-10.25
EX-10.26
EX-10.27
EX-10.28
EX-10.29
EX-10.30
EX-21.1
EX-23.1
EX-FILING FEES
281
08/15/22
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
27
06/23/22
S-1
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-4.2
EX-23.1
EX-FILING FEES
78
05/13/22
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
23
03/21/22
10-K
Annual report pursuant to Section 13 and 15(d)
Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
51
03/09/22
8-K
Current report filing
Documents
EX-99.1
5
03/01/22
8-K
Current report filing
Documents
EX-99.1
4
02/04/22
SC 13G/A
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
6
Previous
1
2
3
4
5
6
7
8
9
10
…16
Next
Email Alerts
Contacts
RSS News Feed